secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001104659-23-037467
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte names Douglas Swirsky as CFO; salary $425K, option for 350K shares
--------------------------------------------------------------------------

- Douglas J. Swirsky appointed CFO and principal accounting officer, effective March 27, 2023.
- He receives $425K base salary, 45% target bonus, and a nonqualified stock option for 350K shares at $4.11/share.
- Option vests over 4 years: 25% after 12 months, then monthly over 36 months.
- Ron Holtz, who served as interim CFO since April 2022, becomes EVP, Administration.
- Swirsky previously CFO of AavantiBio and CEO of Rexahn and GenVec; chairman of Cellectar Biosciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/0001104659-23-037467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/tm2310656d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-037467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer